AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Shares of Glenmark gained 10% to Rs 2,094 on July 11, making it a top gainer on the Nifty Midcap 150 index. Mankind Pharma, NMDC, Gland, and Alkem Lab were also among the top gainers. Moneycontrol ...

Glenmark Pharma shares surged by 10% to hit the upper circuit level in early trade, reaching Rs 2094.40. This significant ...

ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 81% based on the firm’s underlying fundamentals and the stock’s valuation.

According to A.I. Stock Analysis, Roku has earned an overall score of 75 out of 100. The stock’s score and upgraded rating are supported by an upbeat earnings call sentiment and favorable technical ...

AbbVie is deploying more capital into its pipeline, which features 50 programs in mid- and late-stage development and over 375 clinical trials. See why ABBV stock is a Buy.

ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 81% based on the firm’s underlying fundamentals and the stock’s valuation.

In Friday’s market session, top Indian corporates like Tata Consultancy Services (TCS), Hindustan Unilever Ltd (HUL), Bharat Forge, and Glenmark Pharma found themselves in focus as global brokerages ...

ASX health stocks fall o.92% over past five days as US President Donald Trump renews threat to impose tariffs on pharmaceutical imports.

AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of venetoclax remain unchanged.

This does not mean that the stock is going to rise in the near-term but ... or by doing your own similarity analysis. According to Benzinga Pro, AbbVie's peer group average for short interest as a ...